Understanding PSMA PET Imaging in Prostate Cancer

Sponsored by Novartis Pharmaceuticals Corporation

The use of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in evaluating prostate cancer has increased in recent years. This presentation will review PSMA PET imaging, including the technology, its impact across the spectrum of prostate cancer stages, and guideline recommendations for PSMA PET use.

Click to download